IL4I1 (part of our risk model) is able to activate AHR through the production of indole metabolites and canine, and is associated with decreased survival rate, promotion of cancer cell movement, and inhibition of adaptive immunity in people with glioma. This evidence concerns the gene IL4I1 and central nervous system cancer.